Transscleral delivery

Abstract

Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

Description

FIELD[0001]Described herein are methods, compositions, and devices for the treatment of ocular diseases by the transscleral delivery of therapeutic agents, particularly the treatment of wet AMD by transscleral delivery of rapamycin.BACKGROUND[0002]The retina of the eye contains the cones and rods that detect light. In the center of the retina is the macula lutea, which is about ⅓ to ½ cm in diameter. The macula provides detailed vision, particularly in the center (the fovea), because the cones are higher in density. Blood vessels, ganglion cells, inner nuclear layer and cells, and the plexiform layers are all displaced to one side (rather than resting above the cones), thereby allowing light a more direct path to the cones.[0003]Under the retina are the choroid, comprising a collection of blood vessels embedded within a fibrous tissue, and the deeply pigmented epithelium, which overlays the choroid layer. The choroidal blood vessels provide nutrition to the retina (particularly its ...

AI Technical Summary

Benefits of technology

[0122]Generally the therapeutic agent and compositions containing the therapeutic agent may be delivered using any delivery system capable of transscleral delivery of a therapeutically effective amount of the therapeutic agent. Delivery systems and routes of administration that may be used include but are not limited to delivery by injection, solid polymer implant, backed solid polymer implant, solid bioadhesive implant; solid implant with anchoring surface, coated suture, coiled fiber, and solid therapeutic agent.

Problems solved by technology

There are a variety of retinal disorders for which there is currently no treatment or for which the current treatment is not optimal.

Retinal disorders such as uveitis (an inflammation of the uveal tract: iris, ciliary body, and choroid), macular degeneration, macular edema, proliferative diabetic retinopathy, and retinal detachment generally are all retinal disorders that are difficult to treat with conventional therapies.

Organization of serous or hemorrhagic exudates escaping from these vessels results in fibrovascular scarring of the macular region with attendant degeneration of the neuroretina, detachment and tears of the retinal pigment epithelium, vitreous hemorrhage and permanent loss of central vision.

Currently there is no optimal treatment for wet AMD.

Unfortunately, AMD subjects with subfoveal lesions subjected to laser treatment experienced a rather precipitous reduction in visual acuity (mean 3 lines) at 3 months follow-up.

Another drawback of the procedure is that vision after surgery is immediately worse.

Unfortunately, even with successful conventional laser photocoagulation, the neovascularization recurs in about 50-70% of eyes (50% over 3 years and >60% at 5 years).

In addition, many subjects who develop CNV are not good candidates for laser therapy because the CNV is too large for laser treatment, or the location cannot be determined so that the physician cannot accurately aim the laser.

Photodynamic therapy, although utilized in up to 50% of new cases of subfoveal CNV has only marginal benefits over natural history, and generally delays progression of visual loss rather than improving vision which is already decreased secondary to the subfoveal lesion.

PDT is neither preventive or definitive.

Several PDT treatments are usually required per subject and additionally, certain subtypes of CNV fare less well than others.

Although there is currently some off label use of intravitreal triamcinolone acetate, there are no other widely accepted therapies for subfoveal CNV.

Uveitis is another retinal disorder that has proven difficult to treat using existing therapies.

Ocular complications of uveitis may produce profound and irreversible loss of vision, especially when unrecognized or treated improperly.

Visual loss may progress over a period of months, and can be very annoying because of the inability to focus clearly.

ME is a common cause of severe visual impairment.

There are currently no approved devices to deliver therapeutic agents to the posterior segment of the eye from a location external to the eye.

Additionally, therapeutic agents are likely to have undesirable side effects when delivered systemically to treat posterior segment disease.

Interior placement, however, will result in a composition or device being present in the interior of the eye, which may have adverse effects on the proper functioning of the eye.

Although transscleral delivery of therapeutic agents to the eye is advantageous, there are many difficulties in developing such delivery mechanisms.

Images